Trial · NCT02503865

Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome

NCT02503865, Phase 1, Phase 2, Completed, Nazarbayev University; results first posted 2015-11-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome. Trials, record NCT02503865. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02503865

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
NCT number: NCT02503865
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 351 participants, actual
Lead sponsor: Nazarbayev University
Conditions: Metabolic Syndrome
Interventions: Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin, "Analimentary detoxication"
First posted: 2015-07-21
Last updated: 2015-11-30
Results first posted: 2015-11-03
Limitations and caveats: We acknowledge the randomized clinical trial have not a large sample size

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Blood Glucose Level	up to 12 weeks	Fasting blood glucose (FBG) (mmole/L) and Two-hour postprandial glucose (THPG) (mmole/L) were measured.
Primary	Systolic/ Diastolic Blood Pressures (mm Hg)	up to 12 weeks	Systolic and Diastolic Blood Pressures (mm Hg) was measured by manual/automatic tonometery
Secondary	Lipid Profile	up to 12 weeks	Blood sample for lipid profile (Cholesterol in mmole/L, High-density Lipoproteids in mmole/L, Triglycerides in mmole/L) was measured
Secondary	Immunoassay Hormones in Blood	up to 12 weeks	Immunoassay Insulin in the blood (in nU/L) was investigated
Secondary	Immunoassay Cortisole in Blood	up to 12 weeks	Immunoassay Cortisole in the blood (nmole/L) was measured

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Blood Glucose Level	up to 12 weeks	mmole/L	MEAN
PRIMARY	Systolic/ Diastolic Blood Pressures (mm Hg)	up to 12 weeks	mm Hg	MEAN
SECONDARY	Lipid Profile	up to 12 weeks	mmole/L	MEAN
SECONDARY	Immunoassay Hormones in Blood	up to 12 weeks	nU/L	MEAN
SECONDARY	Immunoassay Cortisole in Blood	up to 12 weeks	nmol/L	MEAN

Source ClinicalTrials.gov

Results by group27

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Blood Glucose Level	Conventional Patient Group	Fasting blood glucose level	6.05	Standard Error 0.46	mmole/L
Blood Glucose Level	Analimentary Detoxication Weight Loss	Fasting blood glucose level	6.43	Standard Error 0.36	mmole/L
Blood Glucose Level	Healthy People	Fasting blood glucose level	4.58	Standard Error 0.18	mmole/L
Blood Glucose Level	Conventional Patient Group	Two-hour postprandial glucose	14.5	Standard Error 0.28	mmole/L
Blood Glucose Level	Analimentary Detoxication Weight Loss	Two-hour postprandial glucose	14.6	Standard Error 0.28	mmole/L
Blood Glucose Level	Healthy People	Two-hour postprandial glucose	5.3	Standard Error 0.14	mmole/L
Systolic/ Diastolic Blood Pressures (mm Hg)	Conventional Patient Group	Systolic Blood Pressures	151.2	Standard Error 1.1	mm Hg
Systolic/ Diastolic Blood Pressures (mm Hg)	Analimentary Detoxication Weight Loss	Systolic Blood Pressures	152.1	Standard Error 1.1	mm Hg
Systolic/ Diastolic Blood Pressures (mm Hg)	Healthy People	Systolic Blood Pressures	121.1	Standard Error 0.7	mm Hg
Systolic/ Diastolic Blood Pressures (mm Hg)	Conventional Patient Group	Diastolic Blood Pressures	94.1	Standard Error 0.7	mm Hg

1 to 10 of 27Source ClinicalTrials.gov

See all 27 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Conventional Patient Group	70
Overall Study	STARTED	Analimentary Detoxication	269
Overall Study	STARTED	Healthy People	66
Overall Study	COMPLETED	Conventional Patient Group	65
Overall Study	COMPLETED	Analimentary Detoxication	222
Overall Study	COMPLETED	Healthy People	64
Overall Study	NOT COMPLETED	Conventional Patient Group	5
Overall Study	NOT COMPLETED	Analimentary Detoxication	47
Overall Study	NOT COMPLETED	Healthy People	2

Source ClinicalTrials.gov

Adverse events9

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	hypertermia	General disorders	Conventional Patient Group	40	65	160
other	hypertermia	General disorders	Analimentary Detoxication	62	222	124
other	hypertermia	General disorders	Healthy People	0	64	0
other	hypertension	Cardiac disorders	Conventional Patient Group	42	65	164
other	hypertension	Cardiac disorders	Analimentary Detoxication	26	222	52
other	hypertension	Cardiac disorders	Healthy People	0	64	0
serious	Indigestions	Gastrointestinal disorders	Conventional Patient Group	29	65	78
serious	Indigestions	Gastrointestinal disorders	Analimentary Detoxication	26	222	26
serious	Indigestions	Gastrointestinal disorders	Healthy People	0	64	0

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Conventional Patient Group
Total, all-cause mortality	Analimentary Detoxication
Total, all-cause mortality	Healthy People
Total, other adverse events	Conventional Patient Group	49	65
Total, other adverse events	Analimentary Detoxication	62	222
Total, other adverse events	Healthy People	0	64
Total, serious adverse events	Conventional Patient Group	29	65
Total, serious adverse events	Analimentary Detoxication	26	222
Total, serious adverse events	Healthy People	0	64

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
22140269	RESULT	PubMed
23176668	BACKGROUND	PubMed
23451166	BACKGROUND	PubMed
28163748	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02503865

GET https://conductscience.org/api/trials/v1/NCT02503865/results?page=2

API reference For AI assistants